Replies to post #146929 on Biotech Values

[dia76ca]

By 'esteemed scientist" I mean...


Philip Thorpe, PhD

Professor UT Southwestern
Endowed Title: Serena S. Simmons Distinguished Chair in Cancer Immunopharmacology

Pharmacology, Simmons Comprehensive Cancer Center

Graduate Program: Cancer Biology
Cell Regulation

Contact Information

UT Southwestern Medical Center
5323 Harry Hines Boulevard
Dallas, Texas 75390

Office Phone: 214-648-1268
Office Fax: [phone]

[e-mail]



Biography


EDUCATION/TRAINING

University of Liverpool, UK BSc 1972 Pharmacology

Clinical Research Centre, London, UK PhD 1976 Immunology

POSITIONS AND EMPLOYMENT

1975-1981 Medical Research Council Fellow, Chester Beatty Research Institute, London, UK

1981-1991 Director, Drug Targeting Laboratory, Imperial Cancer Research Fund, London, UK

1991-1998 Professor of Pharmacology, UT Southwestern Medical Center

1998-1999 Associate Director, Center for Molecular Medicine, Maine Medical Center, ME

1999-Present Serena Simmons Distinguished Chair in Cancer Immunopharmacology, Professor of Pharmacology, UT Southwestern

OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS

1998 Chairman, Gordon Research Conference on Drug Carriers in Medicine and Biology, Ventura, CA

2002 Chairman, 1st International Symposium on Vascular Targeting, Boston, MA

2004 Chairman, 2nd International Symposium on Vascular Targeting, Miami, FL

2004-Present American Cancer Society Institutional Review Group Honors

1972 1st Class honors (summa cum laude), Bachelor of Science Degree

1988 1st recipient of Pierce Immunotoxin Award (awarded every two years for outstanding contributions to immunotoxin research)

1997 Texas State Legislature Award for Research Excellence 1999 American Cancer Society Award of Excellence

PATENTS

252 issued and pending worldwide patents (including 74 in the US)

PUBLICATIONS

200 publications in fields of drug targeting, angiogenesis, antibody-based therapeutics.




Education




Graduate School

University of London - England (1975)



Undergraduate

University of Liverpool - England (1972)



Research Interests


Angiogenesis and anti-angiogenic therapeutics

Anti-viral therapeutics that target host determinants on virally infected cells

Antibody-drug conjugates and immunotoxins

Development of novel phosphatidylserine-targeting thererapeutics

Imaging cancer for prediction of tumor response to therapy

Phosphatidylserine

Regulation of tumor immunosuppression

Vascular targeting agents


Publications



Featured
Increased exposure of anionic phospholipids on the surface of tumor blood vessels
Ran S, Downes A, Thorpe PE , Cancer Research , 2002; (62):6132-6140


Featured
In vitro and in vivo studies of a VEGF-121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors
Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Thorpe PE, Walterberger J, Rosenblum MG , Proceedings of the National Academies of Science (USA) , 2002; (99):7866-7871


Featured
Vascular endothelial growth factor as a marker of tumor endothelium
Brekken RA, King SW, Thorpe PE , Cancer Research , 1998; (58):1952-1959


Featured
Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE , Science , 1997; (275):547-550


Featured
Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature
Burrows FJ, Thorpe PE , Proceedings of the National Academies of Science (USA) , 1993; (90):8996-9000

Development of novel CXCR4-based therapeutics.
Peled A, Wald O, Burger J, Expert opinion on investigational drugs, 2012 Mar; 21 (3):341-53

Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine.
Huang X, Ye D, Thorpe PE, Vaccine, 2011 Jun; 29 (29-30):4785-93

Increased exposure of phosphatidylethanolamine on the surface of tumor vascular endothelium.
Stafford JH, Thorpe PE, Neoplasia (New York, N.Y.), 2011 Apr; 13 (4):299-308

Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer.
Sierko E, Wojtukiewicz MZ, Zimnoch L, Thorpe PE, Brekken RA, Kisiel W, Anticancer research, 2011 Mar; 31 (3):843-7

Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via ß2GPI and apoER2.
Ramesh S, Morrell CN, Tarango C, Thomas GD, Yuhanna IS, Girardi G, Herz J, Urbanus RT, de Groot PG, Thorpe PE, Salmon JE, Shaul PW, Mineo C, The Journal of clinical investigation, 2011 Jan; 121 (1):120-31

[bladerunner1717]

dia76ca

CVM has plenty of reputable doctors giving presentations and probably still does, and that doesn't mean that CVM isn't a scam. I bet HEB has the same thing. This doesn't prove the company isn't a scam or that the scientific explanations "prove" anything. And I bet that you don't have the scientific understanding to understand what Thorpe is really saying and you don't have the knowledge to critique it. You should listen to the knowledgeable posters on this board.


Bladerunner

P.S. I DID listen to the presentation.

[iwfal]

PPHM -

.Have you listened to Dr. Thorpe's presentation? I suggest the answer is "NO". And by the way there is a lot of good human data

I would suggest it is you, not I, ignoring the other persons argument since you've ignored my main point (PPHM mgt notoriously overblows their data) - whereas I did actually listen to about 1/2 the presentation. It's almost all MOA data with a little animal data. While my opinion on MOA data at this stage of the game (post ph ii) may be a little more extreme than most on this board I think I'd still be safe in saying that that at this point at best MOA data should be icing, not the cake. The data needs to speak and there is little speaking going on.

As for good human data - single arm trial data with verbal hints of other data after 6 years in the clinic is not particularly good.

PS although I might watch the evolution just as a curiosity, I do not intend to respond more in this thread. I was just trying to help you understand the perspective of many of the members of this board - but I have no interest in spending further time on it.